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ABSTRACT 41 
Acute respiratory distress syndrome is a life-threatening critical syndrome resulting largely 42 
from the accumulation of and inability to clear pulmonary edema. Protectin DX, as an 43 
endogenously produced lipid mediator, is believed to exert anti-inflammatory and 44 
pro-resolution actions. Protectin DX (5ug/kg) was injected i.v. 8 h after LPS (14mg/kg) 45 
administration and alveolar fluid clearance was measured in live rats (n=8). In primary rat 46 
ATII epithelial cells, Protectin DX (3.605×10-3mg/L) was added to the culture medium with 47 
LPS for 6 h. Protectin DX improved alveolar fluid clearance (9.65±1.60 vs. 15.85±1.49, 48 
p<0.0001) and decreased pulmonary edema and lung injury in LPS-induced lung injury in rats. 49 
Protectin DX markedly regulated alveolar fluid clearance with up-regulating the protein 50 
expression of sodium channel and Na,K-ATPase in vivo and in vitro. Protectin DX also 51 
increased the activity of Na,K-ATPase and up-regulated P-Akt via inhibition of Nedd4-2 in 52 
vivo. Besides, Protectin DX enhanced the subcellular distribution of sodium channel and 53 
Na,K-ATPase, specifically localized to the apical and basal membrane of the primary rat ATII 54 
cells. Furthermore, BOC-2, Rp-cAMP, and LY294002 blocked the increased alveolar fluid 55 
clearance response to Protectin DX. Protectin DX stimulates alveolar fluid clearance through 56 
a mechanism partly dependent on alveolar epithelial sodium channel and Na,K-ATPase 57 
activation via the ALX/PI3K/Nedd4-2 signaling pathway. 58 
Key Words: Acute respiratory distress syndrome; Pulmonary edema; alveolar type II cell; 59 
Protectin 60 
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INTRODUCTION 61 
Acute respiratory distress syndrome (ARDS) is a devastating clinical syndrome characterized 62 
by alveolar epithelial injury leading to non-cardiogenic pulmonary edema of flooding 63 
protein-rich in the fluid alveolar spaces1,2. Although our understanding of the 64 
pathophysiological changes associated with ARDS has improved now, there is still none 65 
effective management of this condition and mortality remains approximately 40%2. It is 66 
reported that alveolar fluid clearance is impaired in the majority of patients with ARDS3. 67 
Hence, timely and effective removal of excessive alveolar edema fluid is great importance for 68 
the better clinical outcomes4. 69 
Alveolar fluid clearance relys on active ion transport, which leads to anosmotic gradient that 70 
drives the movement of fluid from the alveolar space back into the interstitium and eventually 71 
to the blood circulation5. The mechanism of alveolar fluid clearance is the alveolar fluid 72 
removed by active Na+ transport across the alveolar epithelium via an apical alveolar sodium 73 
channel6 and through basolateral Na,K-ATPases7. Although therapies such as A2B adenosine 74 
receptor8, angiotensin9, Triiodo-L-thyronine10, Estradiol11, have shown promising clinical 75 
effects in animal models, these have failed to translate positively in human studies12. We 76 
previously reported that an intravenous β-agonist (salbutamol) decreased extravascular lung 77 
water in ARDS patients13,14. However, we found that the side effects of salbutamol, such as 78 
tachycardia, arrhythmia, and lactic acidosis significantly, increased the 28-day mortality rate 79 
in a multicenter, randomized, controlled clinical trial15. Therefore, new therapeutic agents 80 
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need to be identified. 81 
Protectins are novel lipid mediators in anti-inflammation and resolution16. Protectin DX is one 82 
of Protectins, an isomer of protectin D117, is believed to exert anti-inflammatory properties 83 
including inhibition of neutrophil activation and regulating inflammatory cytokines. It is 84 
produced by an apparent double lipoxygenase-mediated reaction in murine perritonitis 85 
exudates, in suspensions of human leukocytes, or by soybean 15- lipoxygenase incubated with 86 
DHA17,18. The mean concentration of Protectin DX in human blood was below 25pg/ml19. The 87 
Protectin DX level in C57BL/6 macrophages was about 60pg/106 cells20, in skeletal muscle of 88 
mice was 30pg/g, in liver was 100pg/g21. The recent study demonstrated that Protectin DX 89 
could block neutrophil infiltration in murine peritonitis by 20-25% at a dose of 1ng/mouse18. 90 
It is reported that Protectin DX could alleviate insulin resistance by activating a myokine-liver 91 
glucoregulatory axis22. Our group previous data suggested that posttreatment with 92 
15-epi-16-parafluorophenoxy lipoxin A4 could attenuate LPS -induced acute lung injury in 93 
mice23. However, there are no studies up to now have addressed the effect of Protectin DX on 94 
pulmonary edema.  95 
The present study tested the hypothesis that administration of Protectin DX will increase 96 
alveolar fluid clearance in LPS–injured rat lungs. Our secondary hypothesis was that 97 
augmented alveolar fluid clearance would also be associated with ATII cells sodium channel, 98 
Na,K-ATPase, P-Akt and Nedd4-2 stimulation after treatment with Protectin DX. Finally, as 99 
the receptors and downstream signalling pathways of Protectin DX are under investigated, we 100 
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investigated the effect of ALX receptor inhibitor (BOC-2), cAMP inhibitor (Rp-cAMP), 101 
cGMP inhibitor (Rp-cGMP), PI3K inhibitor (LY294002), and PKA inhibitor (H89) on 102 
alveolar fluid clearance in ARDS to gain a better understanding of the mechanisms. 103 
METERIALS AND METHODS 104 
Materials 105 
Protectin DX, LY294002 (PI3K inhibitor), and H89 (PKA inhibitor) were from Cayman 106 
Chemical Company (Ann Arbor, MI). LPS (Escherichia coli serotype055:B5) was purchased 107 
from Sigma (St. Louis, MO). Interleukin-1 (IL-1), Interleukin-10(IL-10), Tumor necrosis 108 
factor-α, myeloperoxidase and cAMP ELISA kits were from R&D Systems (Minneapolis, 109 
MN). BOC-2 (ALX inhibitor), Rp-cAMP (cAMP inhibitor), and Rp-cGMP (cGMP inhibitor) 110 
were obtained from Biomol-Enzo Life Sciences (Farmingdale, NY). Anti-Na,K-ATPase α1 111 
and β1were purchased from Abcam (Cambridge, MA), anti- sodium channel α, β, γ were 112 
purchased from Biorbyt (Cambridge, Cambridgeshire). Anti- P-Akt and Total Akt (T-Akt) 113 
and Nedd4-2 were obtained from Cell Signaling Technology (Beverly, MA). 114 
Animal preparation 115 
Specific pathogen-free adult male Sprague-Dawley rats, weighing 250-300 g, obtained from 116 
Slac Laboratory Animal (Shanghai, China), were housed under controlled temperature and 117 
humidity in a day-night cycle, with free access to food and water with the Guide for the Care 118 
and Use of Laboratory Animals. The study was approved by the Animal Studies Ethics 119 
Committee of Wenzhou Medical University. 120 
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Rats were randomized into ten groups (n=8): Control group, LPS group, LPS+Alcohol group 121 
(Protectin DX’s solvent, 50ul/kg), PDX group, LPS+PDX group, LPS+PDX+BOC-2 group, 122 
LPS+PDX+RP-cAMP group, LPS+PDX+ RP-cGMP group, LPS+PDX+H89 group and 123 
LPS+PDX+LY294002 group (PDX= Protectin DX). The LPS-induced lung injury model was 124 
produced by 14 mg/kg of LPS injected via caudal vein. In Protectin DX group, Control group, 125 
rats received Protectin DX (5ug/kg) or equivalent volume of saline via caudal vein. In 126 
LPS+PDX group, LPS+Alcohol group, rats received Protectin DX or alcohol (50ul/kg) via 127 
caudal vein 8 h after LPS exposure. In  LPS+PDX+BOC-2 group, LPS+PDX+RP-cAMP 128 
group, LPS+PDX+RP-cGMP group, LPS+PDX+H89 group and LPS+PDX+LY294002 129 
group, rats received Protectin DX with BOC-2 (600ng/kg), or RP-cAMP (5mg/kg), or 130 
RP-cGMP (5.5 mg/kg), or H89 (10 mg/kg), or LY294002 (3mg/kg) via caudal vein 8 h after 131 
LPS exposure. Before a tracheotomy tube was placed, rats were anesthetized with an i.p. 132 
injection of 5% chloral hydrate (7 ml/kg). Subsequently, Rats were sacrificed after sustained 133 
60 minutes of mechanical ventilation was provided to them, and lungs were harvested.  134 
Pathological studies 135 
The right lower lung lobes were harvested and fixed in 4% paraformaldehyde for 24 h, then 136 
embedded in paraffin and stained with hematoxylin and eosin (H&E) for light microscope 137 
analysis. A semi-quantitative scoring system was adopted to evaluate the lung injury 138 
including alveolar congestion, alveolar hemorrhage, infiltration or aggregation of neutrophils 139 
in the airspace or vessel wall, and thickness of alveolar wall/hyaline membrane formation and 140 
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inflammatory cell infiltration. The grading scale of pathologic findings was used in a light 141 
microscope as follows: 0 = no injury; 1 = slight injury (25%); 2 = moderate injury (50%); 3 = 142 
severe injury (75%); and 4 = very severe injury (almost 100%). The results were graded from 143 
0 to 4 for each item, as described previously27,28. The four variables were summed to represent 144 
the lung injury score (total score: 0-16).  145 
Part of the right lung was homogenized from individual rats and centrifuged, and the tissue 146 
level of myeloperoxidase, TNF-α, IL-1, IL-10 in the resulting supernatants was respectively 147 
determined using myeloperoxidase, TNF-α, IL-1 and IL-10 ELISA kit. 148 
Transmission electron microscopy 149 
Blocks were rinsed overnight in 0.1 M phosphate buffer (350 mOsm, pH 7.4) and postfixed 150 
for two hours in osmium tetroxide (1% osmium tetroxide in 0.125 sodium cacodylate buffer; 151 
400 mOsm, pH 7.4). The samples were then passed through stepwise dehydration in 152 
increasing concentrations of ethanol (50-100 percent), rinsed with propylene oxide and 153 
embedded in Araldite. Blocks were then cut into ultra thin sections (50-70 nm) and contrast 154 
stained with saturated uranyl acetate and bismuth subnitrate. Sections were examined at an 155 
accelerating voltage of 60 kV using a Zeiss EM 10C transmission electron microscope. 156 
Micrographs of a carbon grating replica were taken for calibration. 157 
Measurement of alveolar fluid clearance in live rats 158 
Alveolar fluid clearance was measured in living rats as previously described11,29,30 with some 159 
modifications. Clearance is expressed as a percentage of total instilled volume cleared after 60 160 
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min. Alveolar fluid clearance was determined by Evans blue-tagged albumin concentration 161 
changes, which has been clearly characterized by our laboratory31. 162 
For preparation of the alveolar instillate, a 5% albumin instillate solution was prepared by 163 
dissolving 50 mg/ml BSA in modified lactated Ringer’s solution: 137 mM NaCl, 4.67 mM 164 
KCl, 1.82 mM CaCl2*2H2O, 1.25 mM MgSO4*7H2O, 5.55 mM dextrose, and 12 mM HEPES. 165 
The pH was adjusted to 7.4 at 37˚C. The albumin solution was labeled with 0.15 mg/ml Evans 166 
blue. In brief, after anesthesia with 5% chloral hydrate (7ml/kg), a polyethylene endotracheal 167 
tube was inserted through a tracheotomy. Rats were ventilated with a constant volume 168 
ventilator (model HX-300 Animal ventilators; Taimeng Company of Chengdu, China) with an 169 
inspired oxygen fraction of 100%, a respiratory rate of 45-50 breaths/min and 4.5±0.2 ml tidal 170 
volumes, positive end expiratory pressure was kept at 2-3 cm H2O during the baseline period. 171 
After tracheotomy, the rats were allowed to stabilize for 10 min. The animals were then 172 
placed in the left lateral decubitus position, and instillation tubing (16G Epidural catheter) 173 
was gently passed through the tracheotomy tube into the left lung. A total of 1.5ml (5ml/kg) of 174 
the instillate solution was instilled at a rate of 0.08 ml/min using a syringe pump. After 175 
instillation was complete, 0.2 ml air was injected to clear the instillation catheter of liquid. 176 
The instillate remaining in the syringe was collected as the initial sample. After instillation, 177 
the catheter was left in place for a duration of 60 min. The final alveolar sample was collected 178 
via the instillation catheter. The concentrations of Evans blue-labeled albumin in the instilled 179 
and aspirated solutions were measured by a spectrophotometer at a wavelength of 621 nm. 180 
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Alveolar fluid clearance was calculated using the following equation: alveolar fluid clearance 181 
= (1-C0/C1), where C0 is the protein concentration of the instillate before instillation, and C1 is 182 
the protein concentration of the sample obtained at the end of 60 min of mechanical 183 
ventilation. 184 
Primary rats ATII cells isolation, culture, and treatment 185 
Primary rats ATII cells were isolated from Sprague-Dawley rats (250-300g) by elastase 186 
digestion of lung tissue and then differentially adhered on IgG-coated plates as described by 187 
Dobbs et al32.The purity of ATII cells was assessed by modified Papanicolaou stain based on 188 
the presence of dark blue inclusions. Cell viability was assessed by trypan blue exclusion 189 
(>95%). ATII cells were seeded onto plastic culture dishes at 1×106/cm2 and cultured in a 5% 190 
CO2, 95% air atmosphere in dulbecco's modified eagle medium containing 10% fetal bovine 191 
serum, 2 Mm L-glutamine, 100 U/ml penicillin, and 0.1 mg/ml streptomycin after isolation. 192 
For all experiments, cells were subcultured into six-well plates and maintained until 193 
subconfluence (80%), and cells were serum deprived for 24 h before the addition of LPS 194 
(1ug/ml) in the presence or absence of Protectin DX (3.605×10-3mg/L). 195 
Western blotting for sodium channel, Na, K-ATPase, P-Akt, Nedd4-2 196 
Proteins were obtained with RIPA lysis buffer (50 mM Tris [pH 7.4], 150 mM NaCl, 1% 197 
Triton X-100,1% sodium deoxycholate, 0.1% sodium dodecyl sulfonate, sodium 198 
orthovanadate, sodium fluoride, ethylene diamine tetraacetic acid, leupeptin) and 199 
phenylmethanesulfonyl fluoride. Samples were ultrasonicated 3 times, for 5s, and then spun at 200 
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12,000×g/min for 30min. Protein concentration of the supernatants were determined by a 201 
bicinchoninic acid protein assay kit (Thermo Scientific, Rockford, IL). Proteins were 202 
separated by 10% sodium dodecyl sulfonate polyacrylamide gels and transferred to 203 
polyvinylidene fluoride membranes. After blocking with 5% nonfat dried milk in TBS 204 
containing 0.05% Tween 20, the membranes were incubated with primary antibodies: sodium 205 
channel α, β, γ (1:500, 1:700, 1:800), Na,K-ATPase α1, β1 (1:500,1:1000), and β-actin 206 
(internal control, 1:500), Akt (1: 1000 ), P-Akt (1: 2000 ) and Nedd4-2 (1:1000) overnight at 207 
4˚C, and then reacted with HRP-conjugated secondary Ab (1:000; Santa Cruz Company) at 208 
room temperature for 1.5 h. The protein bands were detected by 209 
electrochemiluminescence (ECL) and visualized by UVP Gel imaging system (Upland, CA). 210 
The band intensity was analyzed by AlphaEaseFC (version 4.0). 211 
Confocal imaging 212 
ATII cells were respectively treated with saline, LPS (1ug/ml), LPS+Alcohol (the same 213 
volume of Protectin DX), LPS+PDX (3.605×10-3mg/L), and Protectin DX for 6h before 214 
fixing in 4% paraformaldehyde and blocked with PBS containing 10%donkey serum for 30 215 
min. The cells were then incubated in a 1:50 dilution of monoclonal mouse anti-Na,K-ATPase 216 
α1, and goat anti- sodium channel α at 4°C for48 h, followed by Alexa Fluor donkey anti-goat 217 
and donkey anti-mouse IgG incubation (1:100 and 1:300; Jackson) at room temperature for 2 218 
h. Cell images were acquired with confocal laser-scanning microscope (Leica) and analyzed 219 
by Image Pro plus 6.3 software (Media Cybernetics, Crofton, MA). 220 
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Measurement of Na,K-ATPase activity in rat lung tissues 221 
The hydrolytic activity of Na,K-ATPase was measured as ouabain-sensitive ATP hydrolysis 222 
under maximal velocity conditions by measuring the release of inorganic phosphate from ATP, 223 
as previously described33. In brief, the rat lung tissues were digested, subjected to centrifugal 224 
sedimentation, lysed, and homogenized. The minimal ATP enzyme test kit (Jian cheng 225 
Company, Nanjing, China) was used to assay Na,K-ATPase activity following manufacturer’s 226 
instructions. 227 
Measurement of cAMP concentration 228 
Lung samples were treated with isobutyryl methylxanthine(Sigma) to inhibit 229 
phosphodiesterases, homogenized in ice-cold1 M TCA, and then centrifuged at 2,500 g to 230 
precipitate particulate material. The cAMP content in the supernatant was measured via 231 
ELISA according to the manufacturer’s instructions (R&D Systems). 232 
Blinding Method 233 
The present study adopted randomized, blinded methods. The randomization list of animals 234 
was computer-generated by the statistician using SAS/STAT software. Blinding was 235 
accomplished by separation of function: a treatment administrator was responsible for 236 
dispensation and administration of animal models. Others specialized in extraction of lung 237 
tissue for Pathological studies, Transmission electron microscopy study, alveolar fluid 238 
clearance measurement and Western blotting et al.  239 
Statistical analysis 240 
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Data are represented as mean ± SD. There were not any missing, lost, or excluded data. Based 241 
on previous experience, no a priori power calculation was conducted, all data were analyzed 242 
by one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons. All tests 243 
were two-sided, significance was determined at the p<0.05 level. Statistical analyses were 244 
performed using Prism 6.0 software (GraphPad Software, San Diego, CA). 245 
 246 
RESULTS 247 
Protectin DX protected lung tissues from LPS-induced acute lung injury in vivo 248 
First, we evaluated the effect of Protectin DX (5ug/kg) on LPS (14mg/kg) -induced acute lung 249 
injury. The control group revealed normal pulmonary histology (Fig.1A,B). Compared with 250 
the control group, lung tissues in the LPS group were markedly damaged with interstitial 251 
edema, hemorrhage, and inflammatory cells infiltration as evidenced by an increase in lung 252 
injury score (Fig.1C). All the morphologic changes were less pronounced in the LPS+PDX 253 
group. Protectin DX significantly reduced LPS-induced pathologic changes by the evidence 254 
of a decrease in lung injury score. There was no significant difference between the control and 255 
Protectin DX groups (Fig. 1C). 256 
In addition, the concentration of myeloperoxidase, TNF-α, IL-1 and IL-10 in the lung tissues 257 
homogenate were significantly increased in the LPS group compared with the control group, 258 
but reduced in the Protectin DX treatment group compared with the LPS group 259 
(Fig.1D,E,F,G). 260 
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Finally, we further tested Protectin DX actions on the ultrastructure of lung tissues. The 261 
lamellar bodies, which is the most significant diagnostic characteristic of ATII, were sever 262 
vacuolated in the LPS group compared with the control group, however, lamellar bodies 263 
recovered in the Protectin DX treatment group (Fig.2A). As shown in Fig.2B, the control 264 
group revealed normal air-blood barrier. In contrast, air-blood barrier in the LPS group was 265 
damaged, broken epithelial bridges and capillary wall appeared in tissues. In treatment group, 266 
Protectin DX significantly improved the air-blood barrier induced by LPS.  267 
Protectin DX upregulated alveolar fluid clearance in LPS-induced acute lung injury in 268 
vivo 269 
Next, we examined the effect of Protectin DX (5ug/kg) on alveolar fluid clearance in LPS 270 
(14mg/kg) -induced acute lung injury in vivo. In all concentration of Protectin DX (1.5, 2.5, 5 271 
and 7.5μg/kg), 1.5ug/kg Protectin DX could not improve the alveolar fluid clearance reduced 272 
by LPS. 2.5μg/kg Protectin DX can improve the alveolar fluid clearance reduced by LPS, and 273 
reached the maximal effect at 5μg/kg, the effect of Protectin DX was similar between 5μg/kg 274 
and 7.5μg/kg. Therefore, Protectin DX at a concentration of 5ug/kg or vehicle alone was 275 
injected through caudal vein 8 h after LPS (14mg/kg) administration, and alveolar fluid 276 
clearance was determined after 60 min. Alveolar fluid clearance in the LPS group was as 277 
expected, reduced compared with the control group (9.65±1.60 vs. 19.23±1.20), whereas 278 
Protectin DX increased alveolar fluid clearance after LPS-induced acute lung injury 279 
(15.85±1.49 vs. 9.65±1.60). However, there was no significant difference between the control 280 
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and Protectin DX groups (Fig.2C). 281 
Protectin DX enhanced sodium channel, Na,K-ATPase in LPS-induced acute lung injury 282 
in vivo 283 
The protein expression of sodium channel α,γ subunits and Na,K-ATPase α1, β1 subunits, but 284 
not β subunit, were increased in the LPS+PDX group compared with the LPS group (14mg/kg) 285 
in rat lung tissue homogenates (Fig.3A-E). In addition, LPS markedly reduced the 286 
Na,K-ATPase activity compared with the control group, whereas Protectin DX (5ug/kg)  287 
heightened Na,K-ATPase activity 8 h after LPS-induced acute lung injury (Fig. 3F). 288 
Protectin DX promoted alveolar fluid clearance through activating the 289 
ALX/cAMP/PI3Kpathway in vivo 290 
To further investigate ALX/cAMP/PI3K-dependent actions of Protectin DX (5ug/kg) in vivo, 291 
firstly, we measured cAMP concentration in lung tissues. We found cAMP concentration was 292 
lessened in the LPS group (14mg/kg) compared with the control group, and Protectin DX 293 
treatment increased cAMP concentration in LPS treated lungs (Fig.4A). In addition, cAMP 294 
concentration were reduced in the LPS+PDX+BOC-2 group and LPS+PDX+LY294002 group  295 
compared with the LPS+PDX group (Fig.4B). Secondly, the protein expression of 296 
Ser473-phos-phorylated Akt in rat lung tissue homogenates was measured by Western blotting. 297 
The protein level of phosphorylated Akt in the LPS group was markedly decreased compared 298 
with control group and observably increased in the LPS+PDX group compared with the LPS 299 
group. BOC-2 (600ng/kg) and LY294002 (3mg/kg) markedly suppressed the Protectin 300 
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DX-induced increased in the protein level of P-Akt (Fig.4C).  301 
Nedd4-2, an E3 ubiquitin-protein ligase, is critical in the negative control of Na+ transport. 302 
The protein level of Nedd4-2 in LPS group was significantly increased compared with the 303 
control group and significantly decreased in the Protectin DX treatment group compared with 304 
the LPS group (Fig.4D). Finally, we co-administered Protectin DX (5ug/kg) and BOC-2 305 
(600ng/kg), Rp-cAMP (5mg/kg), Rp-cGMP (5.5mg/kg), LY294002 (3mg/kg) or H89 (10 306 
mg/kg) to rats through caudal vein 8 h after LPS (14mg/kg) administration, and alveolar fluid 307 
clearance was determined after 60 min. Alveolar fluid clearance in the LPS+PDX+BOC-2 308 
group (11.94±1.56), LPS+PDX+Rp-cAMP group (11.90 ± 1.36) and LPS+PDX+LY294002 309 
group (10.81±1.49) was reduced compared with LPS+PDX group (15.85±1.49), whereas 310 
there was no significant changes in the LPS+PDX+Rp-cGMP and LPS+PDX+H89 groups 311 
(Fig.4E). The beneficial effect of Protectin DX on pulmonary histology was abrogated by 312 
treatment with BOC-2, Rp-cAMP and LY294002 (Supplementary Figure). 313 
Dose and time dependency Protectin DX regulated Na,K-ATPase α1 expression in 314 
primary ATII cells 315 
Different concentrations of Protectin DX including 3.605×10-4, 3.605×10-3, 18.025×10-3, 316 
3.605×10-1 mg/L was incubated with primary ATII cells. As shown in Fig.5A, the 317 
Na,K-ATPase α1 subunit expression was increased dose-dependently with a concentration of 318 
3.605×10-3mg/L producing a maximal effect. In subsequent experiments, the sodium channel 319 
and Na,K-ATPase expression in ATII cells was assessed using 3.605×10-3mg/L Protectin DX. 320 
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The dynamic expression of Na,K-ATPase α1 subunit in primary II cells was significantly 321 
increased at 6h (Fig.5B ). 322 
Protectin DX increased the expression of sodium channel, Na,K-ATPase in primary rat 323 
ATII cells 324 
In vitro, rat primary ATII alveolar epithelial cells were incubated with Protectin DX (3.605×325 
10-3mg/L) in the presence or absence of LPS (1ug/ml) for 6 h at 37°C. Protectin DX increased 326 
sodium channel α (Fig.6A) and Na,K-ATPase α1 (Fig.6B) by confocal laser-scanning 327 
microscopy. The protein expression of sodium channel α , γ subunits and Na,K-ATPase α1, 328 
β1 subunit, but not sodium channel β subunit, were increased in the LPS+PDX group 329 
compared with the LPS group (Fig. 6C, D).  330 
 331 
DISCUSSION  332 
In the present study, we have provided evidence for the pro-resolution actions of Protectin 333 
DX in acute lung injury. Treatment with Protectin DX improved alveolar fluid clearance and 334 
decreased pulmonary edema and lung injury in LPS-induced acute lung injury in rats. 335 
Protectin DX markedly regulated alveolar fluid clearance via up-regulating the protein 336 
expression of sodium channel and Na,K-ATPase in vivo and in vitro. Protectin DX also 337 
increased the activity of Na,K-ATPase in vivo. Besides, Protectin DX enhanced the 338 
subcellular distribution of sodium channel and Na,K-ATPase, specifically localized to the 339 
apical and basal membrane of the primary rat ATII cells. Furthermore, BOC-2, Rp-cAMP, 340 
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and LY294002 blocked the increased alveolar fluid clearance response to Protectin DX. The 341 
results above indicated that Protectin DX increased the expression of sodium channel and 342 
Na,K-ATPase to promote alveolar fluid clearance via the ALX/cAMP/Nedd4-2 343 
signalingpathway. 344 
Acute lung injury is a critical illness syndrome characterized by an increased permeability of 345 
the alveolar-capillary barrier resulting in impairment of alveolar fluid clearance27. So far, no 346 
specific therapy is currently available to modulate this inflammatory response28. It is widely 347 
accepted that resolution of alveolar edema is the crucial step to patient survival4. Our data 348 
clearly demonstrate that Protectin DX significantly improved the air-blood barrier and 349 
lamellar body structure challenged by LPS, especially enhanced the rate of alveolar fluid 350 
clearance 8 h after LPS challenge, and no effect on alveolar fluid clearance in healthy rat 351 
lungs, indicating that Protectin DX plays an important role in the resolution of inflammation. 352 
It is well known that active Na+ transport is the dominant ion transport mechanism involved in 353 
alveolar liquid clearance5. The cellular and molecular mechanisms responsible for the 354 
vectorial transport of Na+ from the alveoli to the interstitium have been reasonably well 355 
defined29. sodium channel is the first constituent of the Na+ transport system, it is expressed in 356 
both alveolar type II and type I cells30. Unable to clear alveolar edema fluid, sodium channel α 357 
gene knockout mice died within 40 h after birth31. Previously, we found that SPMs, such as 358 
lipoxin, resovin could improve the alveolar fluid clearance via regulating sodium channel, 359 
cystic fibrosis transmembrane conductance regulator (CFTR) or aquaporin. In our study, 360 
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Protectin DX not only enhanced lung tissues homogenate sodium channel α and γ subunits 361 
protein expression in LPS-induced acute lung injury, but also increased sodium channel α and 362 
γ subunits protein expression in primary ATII cells stimulated with LPS. Meanwhile, confocal 363 
laser-scanning microscopy results of primary ATII cells draw identical outcomes. Consistent 364 
with our findings, similar results have shown that up-regulation of sodium channel increased 365 
pulmonary edema fluid reabsorption and reduced sodium channel expression delayed 366 
reabsorption of fluid during pulmonary edema after thiourea-induced lung injury32. These 367 
findings, therefore, suggest that Protectin DX promotes alveolar fluid clearance through 368 
up-regulation the expression of sodium channel. 369 
Na+ enters the cell by the amiloride-sensitive sodium channel or by other cationic channels 370 
located at the apical surface, and is extruded by Na,K-ATPase located at the basolateral 371 
surface. It is reported that inhibition or loss of Na,K-ATPase could markedly decrease solute 372 
and fluid transport in alveoli7. Previous studies showed that up-regulation of sodium channel 373 
and Na,K-ATPase increased active Na+ transport, leading to increased ability of the lungs to 374 
clear edema27,33. Impairment of Na,K-ATPase function appears to be a hallmark during lung 375 
injury even in a preclinical stage27,34. In our study, we demonstrated that Protectin DX not 376 
only increased Na,K-ATPase α1,β1 expression in rat lung tissues and primary ATII cells after 377 
LPS challenge by Western blotting and confocal laser-scanning microscopy measurement, but 378 
also up-regulation of Na,K-ATPase activity in vivo. Together, the lung tissues and cell culture 379 
data indicate that Protectin DX promotes alveolar fluid clearance through both of the essential 380 
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mechanisms of sodium channel and Na,K-ATPase. 381 
Specialized pro-resolving mediators (SPMs) derived from ω-3 polyunsaturated fatty acids 382 
orchestrate resolution in diverse settings of acute inflammation35. As one of SPMs family, the 383 
side effect of Protectin DX in low-dose was little, but the high-dose of Protectin DX may 384 
induce calcium ions inflex. So far the receptors and downstream signaling pathways of 385 
Protectin DX are under investigated. It has been generally believed that SPMs exert their 386 
actions by interacting with G-protein-coupled receptor (GPCR) with high affinity and 387 
stereospecificity36,37. Previously, two G protein-coupled receptors (GPCRs) of Resolvin D1 388 
were identified, and validated using a GPCR/arrestin-coupled system, namely, OrphanGPR32 389 
and ALX (the lipoxin A4 receptor, formyl-peptide receptor type 2 [FPR2], also called ALX)38. 390 
It was the first receptor cloned and identified as a GPCR for lipoxin and resolvin with 391 
demonstrated cell-type-specific signalling pathways39,40. In our study, Protectin DX increased 392 
alveolar fluid clearance, but the beneficial effects were abrogated by ALX antagonist (BOC-2) 393 
in vivo, suggesting that the Protectin DX response is ALX dependent. 394 
cAMP and cGMP are important second messengers by which cells transduce extracellular 395 
signals into intracellular responses pathways. Extracellular signals interact with GPCRs to 396 
activate the adenylate cyclase and increase the intracellular cAMP levels. A previous study 397 
showed that LPS-induced immune response leaded to a decrease of intracellular cAMP. 398 
Another study showed that stimulation with cAMP not only increased Na+ transport within 5 399 
min, but also promoted Na,K-ATPase recruitment to the plasma membrane41,42. Extracellular 400 
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signals also interact with GPCR to activate theguanylyl cyclases and increase the intracellular 401 
cGMP levels. In this context, there is evidence for substantial compartmentalization of two 402 
signaling pathways on regulating alveolar fluid clearance, cAMP and cGMP. In accordance 403 
with previously, the intracellular cAMP level was decreased after LPS stimulation, and 404 
Protectin DX abrogated the decrease observed in the LPS group in vivo. As further proof, 405 
Rp-cAMP and Rp-cGMP were used in vivo, of interesting, we found that the Rp-cAMP, not 406 
Rp-cGMP, reduced alveolar fluid clearance in LPS-induced acute lung injury, indicating that 407 
Protectin DX promoted alveolar fluid clearance by activating cAMP via ALX, but not cGMP. 408 
It is well-known that PI3K signals are implicated in regulating sodium channel trafficking and 409 
activity43. The PI3K has been identified for regulation of sodium channel-mediated alveolar 410 
fluid clearance by insulin44. Against this background, our purpose was to evaluate whether the 411 
role of Protectin DX on lung is ALX/cAMP/PI3K dependent. Our studies illustrated that the 412 
intracellular cAMP level was decreased after LPS stimulation, and Protectin DX abrogated 413 
the decrease observed in the LPS group in vivo. Furthermore, we found that Protectin DX 414 
-induced increase in the levels of cAMP blocked with BOC-2and LY294002. Moreover, 415 
BOC-2 and LY294002 blocked the increased alveolar fluid clearance in Protectin DX 416 
treatment group. These results, taken together, manifesting that the Protectin DX response is 417 
ALX/cAMP/PI3K dependent. 418 
It is well accepted that Akt is one of the signaling cascade downstream of PI3K, which is 419 
believed to be the central mediator of signaling with profound effects on several physiological 420 
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events45,46. Our studies revealed that P-Akt (ser473) was decreased after LPS stimulation and 421 
Protectin DX reversed the decreased of P-Akt (ser473), but the beneficial effects were 422 
abrogated by BOC-2 and LY 294002. The implication for our work is that Protectin DX 423 
promoted alveolar fluid clearance by PI3K/Akt signalling pathway.  424 
Nedd4-2, which has been shown to negatively regulate sodium channel expression in vitro 425 
and in vivo47,48. Recent studies using Nedd4-2-deficient mice clearly demonstrated that 426 
Nedd4-2, which is co-expressed with sodium channel in lung epithelial cells transporting Na+, 427 
plays a crucial role in the regulation of sodium channel activity in the lung49. Another study of 428 
Fisher rat thyroid cell proved the regulation of α-, β- and γ-sodium channel heterologously 429 
expressed via PI3K/Akt pathway by suppression of Nedd4-254.Consistently, we also found 430 
Protectin DX inhibited the increase of Nedd4-2 protein expression induced by LPS, the 431 
beneficial effect of Protectin DX on reducing Nedd4-2 protein expression was abolished by 432 
BOC-2 and LY294002 in vivo.  433 
Our study demonstrates that Protectin DX alleviated pulmonary edema, enhanced alveolar 434 
fluid clearance, and attenuated lung injury partially through stimulation of sodium channel 435 
and Na,K-ATPase via activation of the ALX/PI3K/Nedd4-2 pathway in LPS-induced acute 436 
lung injury without affecting normal lung(Fig.7). Thus, treatment with Protectin DX in 437 
critically ill patients with acute lung injury has the potential to augment lung edema clearance. 438 
Our findings reveal a novel mechanism for pulmonary edema fluid reabsorption and Protectin 439 
DX may provide a new therapy for the resolution of ARDS. 440 
    
23 
 
ACKNOWLEDGMENTS 441 
The authors thank Hong-Xia Mei, Wang-Ning Shangguan, Jun Li for technical assistance.  442 
 443 
Conflict of Interest: Conflict of Interest: No conflict of interest exists for any of the above 444 
named authors contributing to this work. 445 
 446 
 447 
 448 
 449 
 450 
 451 
 452 
 453 
 454 
 455 
 456 
 457 
 458 
 459 
 460 
    
24 
 
REFERENCES 461 
1. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000; 342: 1334-49. 462 
2. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, et al. Incidence and outcomes of 463 
acute lung injury. N Engl J Med 2005; 353: 1685-93. 464 
3. Ware LB, Matthay MA. Alveolar fluid clearance is impaired in the majority of patients with acute lung 465 
injury and the acute respiratory distress syndrome. AM J RESP CRIT CARE 2001; 163: 1376-1383. 466 
4. Sznajder JI. Alveolar edema must be cleared for the acute respiratory distress syndrome patient to survive. 467 
Am J Respir Crit Care Med 2001; 163: 1293-4. 468 
5. Matthay MA, Folkesson HG, Clerici C. Lung epithelial fluid transport and the resolution of pulmonary 469 
edema. Physiol Rev 2002; 82: 569-600. 470 
6. Matalon S, O'Brodovich H. Sodium channels in alveolar epithelial cells: molecular characterization, 471 
biophysical properties, and physiological significance. Annu Rev Physiol 1999; 61: 627-61. 472 
7. Sznajder JI, Factor P, Ingbar DH. Invited review: lung edema clearance: role of Na(+)-K(+)-ATPase. J Appl 473 
Physiol 2002; 93: 1860-6. 474 
8. Eckle T, Grenz A, Laucher S,  Eltzschig HK. A2B adenosine receptor signaling attenuates acute lung injury 475 
by enhancing alveolar fluid clearance in mice. J Clin Invest 2008; 118: 3301-15. 476 
9. Deng J, Wang DX, Deng W, Li CY, Tong J. The effect of endogenous angiotensin II on alveolar fluid 477 
clearance in rats with acute lung injury. Can Respir J 2012; 19: 311-8. 478 
10. Bhargava M, Runyon MR, Smirnov D, Lei J, Groppoli TJ, Mariash CN, et al. Triiodo-L-thyronine rapidly 479 
stimulates alveolar fluid clearance in normal and hyperoxia-injured lungs. Am J Respir Crit Care Med 2008; 480 
178: 506-12. 481 
11. Qi D, He J, Wang D, Deng W, Zhao Y, Ye Y, et al. 17beta-estradiol suppresses lipopolysaccharide-induced 482 
acute lung injury through PI3K/Akt/SGK1 mediated up-regulation of epithelial sodium channel (ENaC) in vivo 483 
and in vitro. Respir Res 2014; 15: 159. 484 
12. Dushianthan A, Grocott MP, Postle AD, Cusack R. Acute respiratory distress syndrome and acute lung 485 
injury. Postgrad Med J 2011; 87: 612-22. 486 
13. Perkins GD, McAuley DF, Thickett DR, Gao F. The beta-agonist lung injury trial (BALTI): a randomized 487 
    
25 
 
placebo-controlled clinical trial. Am J Respir Crit Care Med 2006; 173: 281-7. 488 
14. O'Kane CM, McKeown SW, Perkins GD, Bassford CR, Gao F, Thickett DR, et al. Salbutamol up-regulates 489 
matrix metalloproteinase-9 in the alveolar space in the acute respiratory distress syndrome. Crit Care Med 2009; 490 
37: 2242-9. 491 
15. Gao Smith F, Perkins GD, Gates S, Young D, McAuley DF, Tunnicliffe W, et al. Effect of intravenous 492 
beta-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, 493 
randomised controlled trial. Lancet 2012; 379: 229-35. 494 
16. Serhan C. Resolvins and protectins: novel lipid mediators in anti-inflammation and resolution. 495 
Scandinavian Journal of Food & Nutrition 2006; 50: 68-78. 496 
17. Chen P, Fenet B, Michaud S, Tomczyk N, Véricel E, Lagarde M, et al. Full characterization of PDX, a 497 
neuroprotectin/protectin D1 isomer, which inhibits blood platelet aggregation. FEBS Lett 2009; 583: 3478-84. 498 
18. Serhan CN, Gotlinger K, Hong S, Lu Y, Siegelman J, Baer T, et al. Anti-inflammatory actions of 499 
neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing 500 
docosatrienes. J Immunol 2006; 176: 1848-59. 501 
19.  Mas E, Croft KD, Zahra P, Barden A, Mori TA. Resolvins D1, D2, and other mediators of self-limited 502 
resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin 503 
Chem  2012;58:1476-84.  504 
20.  Lee S, Nakahira K, Dalli J, Siempos II, Norris PC, Colas RA, et al. NLRP3 Inflammasome 505 
Deficiency Protects Against Microbial Sepsis via Increased Lipoxin B4Synthesis. Am J Respir Crit Care 506 
Med 2017 Feb 28. 507 
21.  Mitchell PL, Nachbar R, Lachance D, St-Pierre P, Trottier J, Barbier O, et al. Treatment with a novel agent 508 
combining docosahexaenoate and metformin increases protectin DX and IL-6 production in skeletal muscle and 509 
reduces insulin resistance in obese diabetic db/db mice. Diabetes Obes Metab 2017;19:313-9. 510 
22. White PJ, St-Pierre P, Charbonneau A, Mitchell PL, St-Amand E, Marcotte B, et al. Protectin DX alleviates 511 
insulin resistance by activating a myokine-liver glucoregulatory axis. Nat Med 2014; 20: 664-9 512 
23. Jin SW, Zhang L, Lian QQ, Liu D, Wu P, Yao SL, et al. Posttreatment with aspirin-triggered lipoxin A4 513 
analog attenuates lipopolysaccharide-induced acute lung injury in mice: the role of heme oxygenase-1. Anesth 514 
    
26 
 
Analg 2007; 104: 369-77. 515 
24. Wang Q, Lian QQ, Li R, Ying BY, He Q, Chen F, et al. Lipoxin A(4) activates alveolar epithelial sodium 516 
channel, Na,K-ATPase, and increases alveolar fluid clearance. Am J Respir Cell Mol Biol 2013; 48: 610-8. 517 
25. Leland GD MC, Robert G. Monoclonal antibodies specific to apical surfaces of rat alveolar type I cells bind 518 
to surfaces of cultured, but not freshly isolated, type II cells. Biochimica et Biophysica A cta 1988; 970: 146-56. 519 
26. Jiang X, Ingbar DH, O'Grady SM. Adrenergic regulation of ion transport across adult alveolar epithelial 520 
cells: effects on Cl- channel activation and transport function in cultures with an apical air interface. J Membr 521 
Biol 2001; 181: 195-204. 522 
27. Sartori C, Matthay MA. Alveolar epithelial fluid transport in acute lung injury: new insights. Eur Respir J 523 
2002; 20: 1299-313. 524 
28. Shyamsundar M, McAuley DF, Ingram RJ, Gibson DS, O'Kane D, McKeown ST, et al. Keratinocyte 525 
growth factor promotes epithelial survival and resolution in a human model of lung injury. Am J Respir Crit 526 
Care Med 2014; 189: 1520-9. 527 
29. Berthiaume Y, Matthay MA. Alveolar edema fluid clearance and acute lung injury. Respir Physiol 528 
Neurobiol 2007; 159: 350-9. 529 
30. Guidot DM, Folkesson HG, Jain L, Sznajder JI, Pittet JF, Matthay MA. Integrating acute lung injury and 530 
regulation of alveolar fluid clearance. Am J Physiol Lung Cell Mol Physiol 2006; 291: L301-6. 531 
31. Hummler E BP, Gatzy J, Beermann F, Beermann F, Verdumo C, Schmidt A. Early death due to defective 532 
neonatal lung liquid clearance in alpha-ENaC-deficient mice. Nat Genet 1996; 12: 325-8. 533 
32. Morty RE, Eickelberg O, Seeger W. Alveolar fluid clearance in acute lung injury: what have we learned 534 
from animal models and clinical studies? Intensive Care Med 2007; 33: 1229-40. 535 
33. Smith LS, Zimmerman JJ, Martin TR. Mechanisms of acute respiratory distress syndrome in children and 536 
adults: a review and suggestions for future research. Pediatr Crit Care Med 2013; 14: 631-43. 537 
34. Guazzi M, Phillips SA, Arena R, Lavie CJ. Endothelial dysfunction and lung capillary injury in 538 
cardiovascular diseases. Prog Cardiovasc Dis 2015; 57: 454-62. 539 
35. Deng B, Wang CW, Arnardottir HH, Li Y, Cheng CY, Dalli J, et al. Maresin biosynthesis and identification 540 
of maresin 2, a new anti-inflammatory and pro-resolving mediator from human macrophages. PLoS One 2014; 9: 541 
    
27 
 
e102362. 542 
36. Serhan CN. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am 543 
J Pathol 2010; 177: 1576-91. 544 
37. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature 2014; 510: 92-101. 545 
38. Krishnamoorthy S, Recchiuti A, Chiang N, et al. Resolvin D1 binds human phagocytes with evidence for 546 
proresolving receptors. Proc Natl Acad Sci U S A 2010; 107: 1660-5. 547 
39. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution 548 
lipid mediators. Nat Rev Immunol 2008; 8: 349-61. 549 
40. Chiang N, Serhan CN, Dahlen SE, Drazen JM, Hay DW, Rovati GE, et al. The lipoxin receptor ALX: 550 
potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev 2006; 58: 463-87. 551 
41. Thomas CP, Campbell JR, Wright PJ, Husted RF. cAMP-stimulated Na+ transport in H441 distal lung 552 
epithelial cells: role of PKA, phosphatidylinositol 3-kinase, and sgk1. Am J Physiol Lung Cell Mol Physiol 2004; 553 
287: L843-L851. 554 
42. Lecuona E, Minin A, Trejo HE, Chen J, Comellas AP, Sun H, et al. Myosin-Va restrains the trafficking of 555 
Na+/K+-ATPase-containing vesicles in alveolar epithelial cells. J Cell Sci 2009; 122: 3915-22. 556 
43. Soundararajan R, Melters D, Shih IC, Wang J, Pearce D. Epithelial sodium channel regulated by differential 557 
composition of a signaling complex. Proc Natl Acad Sci U S A 2009; 106: 7804-9. 558 
44. Deng W, Li CY, Tong J, Zhang W, Wang DX. Regulation of ENaC-mediated alveolar fluid clearance by 559 
insulin via PI3K/Akt pathway in LPS-induced acute lung injury. Respir Res 2012; 13: 29. 560 
45. Lee IH, Dinudom A, Sanchez-Perez A, Kumar S, Cook DI. Akt mediates the effect of insulin on epithelial 561 
sodium channels by inhibiting Nedd4-2. J Biol Chem 2007; 282: 29866-73. 562 
46. Mattes C, Laube M, Thome UH. Rapid elevation of sodium transport through insulin is mediated by AKT 563 
in alveolar cells. Physiol Rep 2014; 2: e00269. 564 
47. Snyder PM, Olson DR, Kabra R, Zhou R, Steines JC. cAMP and serum and glucocorticoid-inducible kinase 565 
(SGK) regulate the epithelial Na(+) channel through convergent phosphorylation of Nedd4-2. J Biol Chem 2004; 566 
279: 45753-8. 567 
48. Zhou R, Snyder PM. Nedd4-2 phosphorylation induces serum and glucocorticoid-regulated kinase (SGK) 568 
    
28 
 
ubiquitination and degradation. J Biol Chem 2005; 280: 4518-23. 569 
49. Gille T, Randrianarison-Pellan N, Goolaerts A, Dard N, Uzunhan Y, Ferrary E, et al. Hypoxia-induced 570 
inhibition of epithelial Na(+) channels in the lung. Role of Nedd4-2 and the ubiquitin-proteasome pathway. Am J 571 
Respir Cell Mol Biol 2014; 50: 526-37. 572 
 573 
 574 
 575 
 576 
 577 
 578 
 579 
 580 
 581 
 582 
 583 
 584 
 585 
 586 
 587 
 588 
 589 
 590 
 591 
 592 
 593 
 594 
    
29 
 
FIGURE LEGENDS 595 
Figure 1 - Protectin DX protected lung tissues in LPS-induced acute lung injury. 596 
Protectin DX (5ug/kg) was administered to Sprague-Dawley rats 8 h after LPS (14mg/kg) 597 
stimulation through caudal vein, ventilating for 60 min, and the effect of Protectin DX was 598 
assessed (A,B) by histology in hematoxylin and eosin -stained sections(original magnification 599 
×100, ×400). Lung injury scores (C) were recorded from0 (no damage) to 16 (maximum 600 
damage) according to the criteria described in Materials and Methods. Lung tissues 601 
myeloperoxidase (D), TNF-α (E), IL-1 (F), IL-10 (G) expression were measured by Elisa to 602 
quantitatively define the resolution of infiltrated cells. 603 
Data are presented as mean ± SD. n = 8. PDX= Protectin DX. MPO=myeloperoxidase. 604 
Alcohol is Protectin DX’s resolvent. **p<0.01 versus control group; †p<0.05, ††p<0.01 versus 605 
LPS group; ‡p<0.05, ‡‡p<0.01 versus LPS+Alcohol group. 606 
Figure 2 - Effect of Protectin DX on the ultrastructure of lung tissues and alveolar fluid 607 
clearance in LPS-induced acute lung injury in vivo 608 
Protectin DX (5ug/kg) was administered to Sprague-Dawley rats 8 h after LPS (14mg/kg) 609 
stimulation through caudal vein, ventilating for 60 min, and the effect of Protectin DX was 610 
assessed by electronmicroscope photomicrographs of lung tissue from rats. The lamellar 611 
bodies in the LPS group were sever vacuolated compared with the control group, however 612 
lamellar bodies recovered in the Protectin DX treatment group (A). The control group 613 
revealed normal air-blood barrier. In contrast, air-blood barrier in the LPS group was damaged, 614 
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broken epithelial bridges and capillary wall appeared in tissues. In treatment group, Protectin 615 
DX significantly improved the air-blood barrier induced by LPS (B). lb, lamellar body; bc, 616 
blood capillary; ac, air capillary; ep, epithelial bridge; en, endothelial cell; ecm, extracellular 617 
matrix of the capillary wall; cn, cell nucleus; er, erythrocyte. 618 
After intratracheal instillation of 5% albumin solution containing Evans blue-labeled albumin 619 
(5ml/kg) through a tracheostomy to the left lung, alveolar fluid clearance was measured over 620 
60 min in ventilated animals. Data are presented as mean ± SD. n = 8. PDX= Protectin DX. 621 
Alcohol is Protectin DX’s resolvent. ** p<0.01 versus control group; ††p<0.01 versus LPS 622 
group; ‡‡p<0.01 versus LPS+Alcohol group. 623 
Figure 3- Protectin DX enhanced sodium channel, Na,K-ATPase expression and 624 
Na,K-ATPase activity in LPS-induced acute lung injury in vivo. 625 
Protectin DX (5ug/kg) was administered to Sprague-Dawley rats 8 h after LPS (14mg/kg) 626 
stimulation through caudal vein, ventilating for 60 min, and the right lung tissue was 627 
harvested to measure the protein expression of sodium channel α, β and γ subunits (A,B,C) 628 
and Na,K-ATPase α1 and β1 subunits (D,E) by Western blotting. In addition, the 629 
Na,K-ATPase activity in lung tissue homogenate was detected by kits (F). Data are presented 630 
as mean ± SD. n =8. PDX= Protectin DX. Alcohol is Protectin DX’s resolvent. *p<0.05, 631 
**p<0.01 versus control group; †p<0.05, ††p<0.01 versus LPS group; ‡p<0.05, ‡‡p<0.01 632 
versus LPS+Alcohol group. 633 
Figure 4–Protectin DX improved alveolar fluid clearance was partly dependent on ALX, 634 
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cAMP and PI3K pathway in vivo.  635 
Protectin DX (5ug/kg) and BOC-2 (ALX receptor inhibitor, 600ng/kg), LY294002 (PI3K 636 
inhibitor, 3mg/kg), Rp-cAMP (5mg/kg), Rp-cGMP (5.5mg/kg) or H89 (10mg/kg) were 637 
co-administered to Sprague-Dawley rats 8 h after LPS (14mg/kg) stimulation through caudal 638 
vein, and intratracheal instillation of 5% albumin solution containing Evans Blue-labeled 639 
albumin (5ml/kg) through a tracheostomy to the left lung to measure alveolar fluid clearance 640 
(E); and the right lung tissue was harvested to measure the cAMP concentration by ELISA 641 
kits (A,B), the protein expression of phosphorylation of Akt (C) and Nedd4-2 (D) by Western 642 
blotting. Data are presented as mean ± SD. n=8. PDX= Protectin DX. Alcohol is Protectin 643 
DX’s resolvent. **p<0.01 versus control group; ††p<0.01 versus LPS group; ‡p<0.05, 644 
‡‡p<0.01 versus LPS+PDX group.  645 
Figure 5-Dose and time dependency of Protectin DX regulated Na,K-ATPase expression 646 
in primary ATII cells.  647 
The dose- and temporal-dependent changes of Na,K-ATPase protein expression in primary 648 
ATII cells stimulated with LPS (1ug/ml) were determined by Western blotting. Cells were 649 
incubated with different concentrations of Protectin DX for 6 h including 3.605×10-4, 3.605650 
×10-3, 18.025×10-3 and 3.605×10-1 mg/L to measure the Na,K-ATPase α1 subunit protein 651 
expression (A). Moreover, ATII cells were incubated with LPS (1ug/ml) for 1, 2, 4, and 6 h to 652 
detect the expression of Na,K-ATPaseα1 subunit protein (B). Data are presented as mean ± 653 
SD. n =8. PDX= Protectin DX. *p<0.05, **p<0.01 versus control group; †p<0.05, ††p<0.01 654 
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versus LPS group. 655 
Figure 6- Protectin DX promoted sodium channel expression in primary rat ATII cells 656 
stimulated with LPS. 657 
Rat primary ATII cells were treated with Protectin DX (3.605×10-3mg/L) in the presence or 658 
absence of LPS (1ug/ml) for 6 h. After incubation, cells were harvested and sonicated. 659 
Sodium channel α (A) and Na,K-ATPase α1 (B) subunits protein expression in the cell lysates 660 
were detected by confocal laser-scanning microscopy using a specific Ab against (original 661 
magnification ×400). In addition, sodium channel α, β, and γ subunits (C) and Na,K-ATPase 662 
α1 and β1 subunits (D) protein expression in the cell lysates were detected by Western 663 
blotting. Data are presented as mean± SD. n = 8. PDX= Protectin DX. Alcohol is Protectin 664 
DX’s resolvent. **p<0.01 versus control group; †p<0.05, ††p<0.01 versus LPS group; ‡p<0.05, 665 
‡‡p<0.01 versus LPS+Alcohol group. 666 
Figure 7- Protectin DX protected LPS-induced acute lung injury in vivo and in vitro. 667 
 668 
 669 
Supplementary figure legends YES  670 
Figure S1. Different inhibitors on histological signs of lung injury 671 








